Cargando…

Human DESC1 serine protease confers tumorigenic properties to MDCK cells and it is upregulated in tumours of different origin

Proteolysis of the extracellular matrix components plays a crucial role in the regulation of the cellular and physiological processes, and different pathologies have been associated with the loss or gain of function of proteolytic enzymes. DESC1 (differentially expressed in squamous cell carcinoma g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viloria, C G, Peinado, J R, Astudillo, A, García-Suárez, O, González, M V, Suárez, C, Cal, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360300/ https://www.ncbi.nlm.nih.gov/pubmed/17579619 http://dx.doi.org/10.1038/sj.bjc.6603856

Ejemplares similares

Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer
por: Soh, C-L, et al.
Publicado: (2014)

Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells
por: Moniaux, N, et al.
Publicado: (2007)

Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential
por: Rieger-Christ, K M, et al.
Publicado: (2005)

Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours
por: White, D E, et al.
Publicado: (2010)

Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo
por: Duivenvoorden, W C, et al.
Publicado: (2013)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Upregulation of calcium-sensing receptor and mitogen-activated protein kinase signalling in the regulation of growth and differentiation in colon carcinoma
por: Bhagavathula, N, et al.
Publicado: (2005)

Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells
por: Lucia, M B, et al.
Publicado: (2011)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells
por: Strillacci, A, et al.
Publicado: (2006)

Sigma-2 ligands induce tumour cell death by multiple signalling pathways
por: Zeng, C, et al.
Publicado: (2012)

Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI
por: Gambarota, G, et al.
Publicado: (2008)

Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines
por: Lindner, D, et al.
Publicado: (2009)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

CCL19 reduces tumour burden in a model of advanced lung cancer
por: Hillinger, S, et al.
Publicado: (2006)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
por: Yang, Y, et al.
Publicado: (2006)

Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
por: Dudley, A C, et al.
Publicado: (2008)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
por: Wang, Y, et al.
Publicado: (2005)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
por: Broadhead, M L, et al.
Publicado: (2011)

The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
por: Steele, J C, et al.
Publicado: (2006)

Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines
por: Stewart, G D, et al.
Publicado: (2008)

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_p36g8joeuivrs3q5epabe8el6m